Melanocortin Receptor Agonists
Bremelanotide
Also known as PT-141 · Vyleesi
FDA-approved for specific indicationsFDA-approved
Last reviewed: 2026-11-19
History
Developed by Palatin Technologies from melanocortin peptide research; FDA approval followed in 2019.
Key sources
Indication-specific regulatory sources and editorial screen checked November 19, 2026. This is not an exhaustive systematic review; consult current labels.